PDF herunterladen
Aktuelle Dermatologie 2012; 38(07): 272-276
DOI: 10.1055/s-0032-1309729
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Merkelzellkarzinom

Merkel Cell Carcinoma
I. Moll
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
07. Mai 2012 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Das Merkelzellkarzinom ist ein hochaggressives neuroendokrines Karzinom der Haut, das klinisch als rasch wachsender, rötlich-bläulich-livider Tumorknoten imponiert. Ulzerationen sind selten. Es betrifft bevorzugt die lichtexponierte Haut sehr alter oder langjährig immunsupprimierter Patienten.

Einen wichtigen Beitrag zur Pathogenese des Merkelzellkarzinoms gelang durch die Entdeckung des Merkelzell-Polyoma-Virus, welches in der Mehrzahl der Fälle nachweisbar und mutiert ist. Das mutierte sog. Large-T-Antigen kann aber noch in den Zellzyklus eingreifen und dadurch die Tumorigenese fördern.

Die Prognosemarker des Merkelzellkarzinoms sind noch umstritten, wichtig ist der Befall der regionalen Lymphknoten.

Therapiestandard ist im Stadium I die Exzision mit Sicherheitsabstand von 3 cm und die adjuvante Strahlentherapie der Tumorregion und evtl. der regionären Lymphknoten. Die Sentinel node biopsy sollte angestrebt werden. Auch im Stadium II ist chirurgische Therapie angezeigt mit nachfolgender Bestrahlung, bei inoperablen Zuständen ist die alleinige Radiatio vergleichbar effektiv. Chemotherapien – noch nicht gut evaluiert – sind Therapie der Wahl im Stadium III mit guten, allerdings meist nur kurzfristigen Remissionen. Daher sind eine Reihe von neuen sog. targeted therapies und Vakzinierungen beim Merkelzellkarzinom in der Diskussion und in klinischen Studien.

Das Merkelzellkarzinom, der bösartigste Tumor der Haut, hat trotz einiger neuerer Erkenntnisse noch immer eine Reihe von Geheimnissen!

Abstract

Merkel cell carcinomas (MCC) are highly aggressive neuroendocrine tumors of skin usually localized in UV-exposed skin of elderly and immunoincompetent patients. The isolation of a new virus, the Merkel cell polyoma virus, in most MCC is a main stay in clarifying the pathogenesis of MCC and especially its so-called Large T antigen seems tumorigenic. This antigen is mutated in MCC but still active in cell cycle regulation, inducing the proliferation of tumor cells.

There are no established markers of prognosis and no evidence based therapeutic procedures.

In stage I there is consent to remove the primary with 2 – 3 cm distance and applying radiation to the tumor bed and the regional lymph nodes. Sentinel node biopsy should be done if possible. Also in tumor stage II surgery and radiation are recommended. Chemotherapies are the first line therapies in stage III but not yet evidence based, usually of limited effect and palliative. Currently, innovative strategies such as targeted therapies and vaccinations are in discussion and under clinical trials. These aspects are discussed in this review paper.

 

  • Literatur

  • 1 Toker C. Trabecular carcinoma of the skin. Arch Dermatol 1972; 105: 107-110
    CrossrefPubMedGoogle Scholar
  • 2 Tang CK, Toker C. Trabecular carcinoma of the skin. An ultrastructural study. Cancer 42 1978; 2311-2321
    PubMedGoogle Scholar
  • 3 Heath M, Jaimes N, Lemos B et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008; 58: 375-381
    CrossrefPubMedGoogle Scholar
  • 4 Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005; 89: 1-4
    CrossrefPubMedGoogle Scholar
  • 5 Allen PJ, Bowne WB, Jaques DP et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 2005; 23: 2300-2309
    CrossrefPubMedGoogle Scholar
  • 6 Medina-Franco H, Urist MM, Fiveash J et al. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 2001; 8: 204-208
    CrossrefPubMedGoogle Scholar
  • 7 Yiengpruksavan A, Coit DG, Thaler HT et al. Merkel cell carconoma: prognosis and management. Arch Surg 1991; 126: 1514-1519
    CrossrefPubMedGoogle Scholar
  • 8 Merkel Cell Carcinoma, Chapter 30. In: Edge SB, Byrd DR, Compton CC, et al., eds AJCC Cancer Staging Manual. 7th. ed. New York: Springer; 2010
    Google Scholar
  • 9 Lemos BD, Storer BE, Iyer JG et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 2010; 63: 751-761
    CrossrefPubMedGoogle Scholar
  • 10 Moll I, Zieger W, Schmelz M. Proliferative Merkel cells were not detected in human skin. Arch Dermatol Res 1996; 288: 184-187
    CrossrefPubMedGoogle Scholar
  • 11 Becker JC. Merkel cell carcinoma. Ann Oncol 2010; 21 (Suppl. 07) vii81-vii85
    CrossrefPubMedGoogle Scholar
  • 12 Houben R, Michel B, Voller-Kanczek CS et al. Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J Invest Dermatol 2006; 126: 1135-1142
    CrossrefPubMedGoogle Scholar
  • 13 Feng H, Shuda M, Chang Y et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096-1100
    CrossrefPubMedGoogle Scholar
  • 14 Foulongne V, Kluger N, Dereure O et al. Merkel cell polyomavirus and Merkel cell carcinoma. France Emerg Infect Dis 2008; 14: 1491-1493
    PubMedGoogle Scholar
  • 15 Shuda M, Feng H, Kwun HJ et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 2008; 105: 16272-16277
    CrossrefPubMedGoogle Scholar
  • 16 Fischer N, Brandner JM, Moll I et al. Detection of Merkel cell polyoma virus (MCPyV) in Merkel cell carcinoma cell lines: cell morphology and growth phenotype do not reflect presence of the virus. Int J Cancer 2010; 126: 2133-2142
    PubMedGoogle Scholar
  • 17 Wong HH, Wang J. Merkel cell carcinoma. Arch Pathol Lab Med 2010; 134: 1711-1776
    PubMedGoogle Scholar
  • 18 Shuda M, Kwun HJ, Feng H et al. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest 2011; 121: 3623-3634
    CrossrefPubMedGoogle Scholar
  • 19 Wieland U, Mauch C, Kreuter A et al. Merkel cell Polyomavirus DNA in persons without Merkel cell carcinoma. Em Infect Diseases 2009; 9: 1496-1498
    PubMedGoogle Scholar
  • 20 Lunder EJ, Stern RS. Merkel cell carcinoma in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med 1998; 339: 1247
    CrossrefPubMedGoogle Scholar
  • 21 Buell JF, Trofe J, Hanaway MJ et al. Immunosuppression and Merkel cell cancer. Transplant Proc 2002; 34: 1780-1781
    CrossrefPubMedGoogle Scholar
  • 22 Engels EA, Frisch M, Goedert JJ et al. Merkel cell carcinoma and HIV infection. Lancet 2002; 359: 497-498
    CrossrefPubMedGoogle Scholar
  • 23 Gould VE, Dardi LE, Memoli VA. Neuroendocrine carcinomas of the skin: Light microscopic, ultrastructural, and immunohistochemical analyses. Ultrastruct Pathol 1980; 1: 499-509
    CrossrefPubMedGoogle Scholar
  • 24 Andea AA, Coit DG, Amin B et al. Merkel cell carcinoma: histologic features and prognosis. Cancer 2008; 113: 2549-2558
    CrossrefPubMedGoogle Scholar
  • 25 Fernandez-Figueras MT, Puig L, Musulen E et al. Prognostic significance of p27kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma. Histopathology 2005; 46: 614-621
    CrossrefPubMedGoogle Scholar
  • 26 Brunner M, Thurnher D, Pammer J et al. Expression of VEGF-A/C, VEGF-R2, PDGF alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and BMI-1 in Merkel cell carcinoma. Mod Pathol 2008; 21: 876-884
    CrossrefPubMedGoogle Scholar
  • 27 Senchenkov A, Barnes SA, Moran SL. Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremities. J Surg Oncol 2007; 95: 229-234
    CrossrefPubMedGoogle Scholar
  • 28 Mojica P, Smith D, Ellenhorn JD. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 2007; 25: 1043-1047
    CrossrefPubMedGoogle Scholar
  • 29 Civantos FJ, Moffat FL, Goodwin WJ. Lymphatic mapping and sentinel lymphadenectomy for 106 head and neck lesions: contrasts between oral cavity and cutaneaous malignancy. Laryngoscope 2006; 116: 1-15
    PubMedGoogle Scholar
  • 30 Maza S, Trefzer U, Hofmann M et al. Impact of sentinel lymph node biopsy in patients with Merkel cell carcinoma: results of a prospective study and review of the literature. Eur J Nucl Med Mol Imaging 2006; 33: 433-440
    CrossrefPubMedGoogle Scholar
  • 31 Mortier L, Mirabel X, Fournier C et al. Radiotherapy alone for primary Merkel cell carcinoma. Arch Dermatol 2003; 139: 1587-1590
    CrossrefPubMedGoogle Scholar
  • 32 Voog E, Biron P, Martin JP et al. Chemotherapy for patients with locally advanced metastatic Merkel cell carcinoma. Cancer 1999; 85: 2589-2595
    CrossrefPubMedGoogle Scholar
  • 33 Eng TY, Boersma MG, Fuller CI et al. A Compehensive Review of the Treatment of Merkel cell Carcinoma. Am J Clin Oncol 2007; 30: 634-636
    PubMedGoogle Scholar
  • 34 Tai PT, Yu E, Winquist E et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000; 18: 2493-2499
    PubMedGoogle Scholar
  • 35 Bichakjian CK, Lowe L, Lao CD et al. Merkel Cell Carcinoma: Critical Review With Guidelines for Multidisciplinary Management. Cancer 2007; 110: 1-12
    CrossrefPubMedGoogle Scholar
  • 36 Houben R, Ortmann S, Schrama D et al. Activation of the MAP kinase pathway induces apoptosis in the Merkel Cell carcinoma cell line UISO. J Invest Dermatol 2007; 127: 2116-2122
    CrossrefPubMedGoogle Scholar
  • 37 Su LD, Fullen DR, Lowe L et al. CD117 (kit receptor) expression in Merkel cell carcinoma. Am J Dermapathol 2002; 24: 289-293
    PubMedGoogle Scholar
  • 38 Samlowski WE, Moon J, Tuthill RJ et al. A Phase II Trial of Imatinib mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin). Am J Clin Oncol 2010; 33: 495-499
    CrossrefPubMedGoogle Scholar
  • 39 Strong S, Shalders K, Carr R et al. KIT receptor (CD 117) expression in Merkel cell carcinoma. Br J Dermatol 2004; 150: 384-385
    CrossrefPubMedGoogle Scholar
  • 40 Jansen B, Heere-Ress E, Schlagbauer-Wadl H et al. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med 1999; 77: 792-797
    CrossrefPubMedGoogle Scholar
  • 41 Feinmesser M, Halpern M, Fenig E et al. Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome?. Hum Pathol 1999; 30: 1367-1372
    CrossrefPubMedGoogle Scholar
  • 42 Shah MH, Varker KA, Collamore M et al. G3139 (Genasense) in patients with advanced merkel cell carcinoma. Am J Clin Oncol 2009; 32: 174-178
    CrossrefPubMedGoogle Scholar
  • 43 Biver-Dalle C, Nguyen T, Touzé A et al. Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyoma virus. Acta Oncol 2011; 50: 479-480
    CrossrefPubMedGoogle Scholar
  • 44 Ely H, Pascucci A. Merkel cell carcinoma: Treatment with bleomycin. Dermatol Online J 2008; 14: 3
    PubMedGoogle Scholar